Last reviewed 2026-04-22 · How we verify

P.O roxithromycin 150 mg*2/d for 7 days

Roxithromycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation and bacterial growth.

Roxithromycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation and bacterial growth. Used for Respiratory tract infections (bronchitis, pneumonia), Skin and soft tissue infections, Urinary tract infections.

At a glance

Mechanism of action

Roxithromycin is a macrolide antibiotic that binds irreversibly to the bacterial 50S ribosomal subunit, blocking translocation of peptides and inhibiting protein synthesis. This bacteriostatic action prevents bacterial replication and allows the immune system to clear the infection. It is effective against a broad spectrum of gram-positive and some gram-negative bacteria, as well as atypical organisms.

Approved indications

• Respiratory tract infections (bronchitis, pneumonia)
• Skin and soft tissue infections
• Otitis media
• Sinusitis
• Urinary tract infections

Common side effects

• Gastrointestinal disturbance (nausea, diarrhea, abdominal pain)
• Headache
• Dizziness
• Rash
• QT prolongation

Key clinical trials

• Comparison of Two Antibiotic Prophylactic Protocols in Preterm Premature Rupture of the Membranes (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• P.O roxithromycin 150 mg*2/d for 7 days CI brief — competitive landscape report
• P.O roxithromycin 150 mg*2/d for 7 days updates RSS · CI watch RSS
• Western Galilee Hospital-Nahariya portfolio CI